Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

Abstract

Purpose: CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies. Experimental Design: Seventeen patients were treated with escalating doses of CT-011 ranging from 0.2 to 6 mg/kg. For pharmacokinetic analysis, blood samples were withdrawn from the patients before and immediately after treatment and at 24 hours, 48 hours, and on days 7, 14, and 21. CT-011blood levels were assessed with a specific ELISA and derived concentrations were used to calculate pharmacokinetic parameters. Activation of the immune system was assessed by measuring peripheral blood CD4 + , CD8 + , and CD69 + lymphocytes. Results: The study showed the antibody to be safe and well tolerated in this patient population. No single maximum tolerated dose was defined in this study. Clinical benefit was observed in 33% of the patients with one complete remission. Pharmacokinetic analyses show that serum C max and the AUC of CT-011 increased proportionally with dose. The median t 1/2 of CT-011 ranged from 217 to 410 hours. Sustained elevation in the percentage of peripheral blood CD4 + lymphocytes was observed up to 21days following CT-011treatment. Conclusions: A single administration of 0.2 to 6.0 mg/kg of CT-011is safe and well tolerated in patients with advanced hematologic malignancies.

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

“…This activation could induce tumor attraction of lymphocytes (Ivashkiv and Donlin, 2014). There are some important implications for one of the most exciting new developments in cancer treatment, immune checkpoint therapy (Berger et al, 2008;Brahmer et al, 2010;Leach et al, 1996;Topalian et al, 2015) (Hodi et al, 2010) (Weber et al, 2015) and for underlying mechanisms inherent to both tumor and host cells for reversal of immune tolerance in tumor infiltrating T-lymphocytes (Pardoll, 2012). Indeed, our basal levels of viral defense gene transcripts divide EOC, and other major cancer types in TCGA, into low and high expression subgroups.…”

B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non–PD-1–Mediated Pathway

“…Indeed, interference with PD-1/B7-H1 interaction reinforced antitumor responses in different cancer models (28)(29)(30). Also, in humans, blockage of B7-H1/PD-1 interaction results in an improved antitumor immune response (31,32). These studies highlight the in vivo relevance of B7-H1-mediated immuneregulatory pathways and the potential of its targeted activation in human diseases.…”

Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas

“…8 This issue is particularly relevant when considering the ongoing trials of immune checkpoint-targeting therapeutic regimens for these aggressive lymphomas. [9][10][11][12][13] To maximize the effects of these innovative therapies, the determinants of response in B-NHL patients must be better understood. In particular, the various immune escape pathways might constitute a mechanism for immune resistance and beyond, to immune checkpoint therapeutic resistance.…”